Darvocet And Darvon Lawsuit

Darvocet And Darvon Lawsuit

By:


On November 19, 2010 Xanodyne Pharmaceuticals Inc. which makes Darvon and Darvocet, the brand name version of the prescription pain medication propoxyphene, has agreed to recall the medication from the US market at the request of the U.S. Food and Drug Administration. The Food and Drug Administration has also informed the generic producers of propoxyphene-containing products of Xanodynes decision and asked that they voluntarily recall their drugs as well.

The Food and Drug Administration sought market removal of propoxyphene immediately after getting new clinical data showing that the medicine puts individuals at risk of possibly severe or even fatal cardiovascular rhythm abnormalities. As a result of these info, combined with other data, which includes new epidemiological data, the agency concluded that the hazards of the medicine outweigh the benefits.

The Food and Drug Administration is satisfied by Xanodynes decision to voluntarily remove its prescription medicines from the U.S. market, said John Jenkins, M.D., director of the Office of New Drugs in the Food and Drug Administrations Center for Drug Evaluation and Research (CDER). These new heart data significantly alter propoxyphenes risk-benefit profile. The drugs effectiveness in reducing pain is no longer enough to outweigh the drugs serious potential heart risks.

The Food and Drug Administration is advising health care professionals to discontinue prescribing propoxyphene to their patients, and patients who are at this time taking the medicine need to call their health care professional as soon as possible to speak about switching to another pain management treatment.

What is propoxyphene?

Propoxyphene is an opioid pain reliever used to treat light to moderate pain. It can be sold under different names as being a single-ingredient product (e.g., Darvon) and as a part of a combo product with acetaminophen (e.g., Darvocet). Propoxyphene is also marketed under such names as Dolene, Propacet 100, Wygesic, SK-65, SK-65 APAP, Trycet, Genagesic, E-Lor, and Balacet.

Why has Food and Drug Administration asked the makers of propoxyphene to remove propoxyphene containing prescription medicines off the market?

Data files from a new study have become available that shows that propoxyphene causes significant changes to the electrical activity of the cardiovascular system, even when the medication is used at therapeutic doses. These adjustments, prolonged PR interval, widened QRS complex and prolonged QT interval, which may be seen on an electrocardiogram (ECG), can increase the danger for severe abnormal heart rhythms.

A patients risk for these cardiac effects while using propoxyphene can change at any time, even when the patient has been taking propoxyphene for quite a few years. A change in the patients disease state, intake of other drugs, or a decrease in kidney function can significantly increase their threat for cardiac effects with propoxyphene.

According to this new information, Food and Drug Administration believes this action is important to ensure patient protection.

If you or maybe a someone you know has become injured by either Darvocet, Davron, or another medicine containing propoxyphene, you ought to get in touch with our attorneys ASAP. Chances are you'll be entitled to compensation by filing a individual lawsuit and we can help.


About the Author:
In the event you or a somebody you know has been injured or killed by either Darvocet, Davron, or another prescription drug containing propoxyphene, you ought to call our lawyers ASAP. You may be entitled to compensation by filing a individual lawsuit and we can help.

Simply click right here to read further:

Darvocet lawsuit



Article Originally Published On: http://www.articlesnatch.com


|

Loading...
Related....
Videos...

Recent Health Articles

Comments

Still can't find what you are looking for? Search for it!

Loading

Copyright 2005-2011 ArticleSnatch, LLC - All Rights Reserved.
Privacy Policy | Terms of Service.